Fresh analysis reveals that individuals who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt conventional lifestyle programs.
Research printed in a prominent medical journal shows that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing such medications must be informed of the danger of fast rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original weight in about one and a half years.
Weighing Therapies
The analysis, which examined dozens of studies involving over 9,000 of participants, contrasted the results of the injectable medications with conventional dieting.
The team emphasize that individuals who lose weight through diet and exercise usually have a slower creep back—approximately 100 grams monthly—once they finish.
Understanding the Fast Regain
Nutrition scientists propose the mechanism of the jabs accounts for the heightened rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone concentrations several times higher than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making excessive eating a significant risk."
A Chronic Condition?
Health authorities recommend the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of weight regain, the treatment should be considered ongoing.
This perspective is supported by pharmaceutical companies, who state that the findings "highlight the persistent nature of obesity," akin to managing conditions like diabetes.
Patient Experiences
People who have stopped the medication explain a powerful return of cravings.
"It was like something that goes on and you're instantly starving," described a patient.
The struggle is exacerbated if users have not adopted permanent lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and long-term success likely depends on integrated behavioural changes.
